|
Issue 1,587:
September 1, 2021
|
 |
 |
|
|
| Top Stories |
|
- Following full FDA licensure, ACIP recommends use of Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) for
individuals age 16 years and older
- Register now for IAC’s September 9 webinar! Our expert panel answers your questions on preventing
influenza during the COVID-19 pandemic.
- “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory
Committee on Immunization Practices, United States, 2021–22 Influenza Season” published in MMWR Recommendations and
Reports
- “COVID-19 Vaccination Coverage among Adolescents Aged 12–17 Years—United States,
December 14, 2020–July 31, 2021” published in MMWR Early Release
- IAC updates its “Ask the Experts: COVID-19” web page to answer questions about FDA
licensure, vaccination during pregnancy, additional doses of mRNA vaccines for immunocompromised people, Guillain-Barré syndrome, and
myocarditis
- IAC Spotlight! IAC's “Clinic Tools: Administering Vaccines” gateway page provides
resources from authoritative sources
- Journalists interview IAC experts
- Vaccines in the news
Immunize.org Pages and Handouts
Vaccine Information Statements
Featured Resources
Notable Publications
Global News
Upcoming Events
Immunization PSAs from the Archive
Top Stories
Following full FDA licensure, ACIP
recommends use of Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) for individuals age 16 years and older
On August 30, the Advisory Committee on Immunization Practices (ACIP) unanimously
(14–0) recommended use of the first COVID-19 vaccine to receive full FDA licensure. On August 23, FDA approved
Pfizer-BioNTech COVID-19 Vaccine, which will now be marketed as Comirnaty, for use in people age 16 years and older. Presentation slides from the meeting are available online.
In reaching this decision, ACIP utilized its Evidence to Recommendations framework to summarize data on the vaccine’s safety and efficacy.
ACIP also considered the benefits and risks of using the vaccine in this population. ACIP members noted that, while the initial emergency use
authorization (EUA) issued in December 2020 was based on information from Phase 2/3 clinical trials with 2 months of follow up, the Committee now has
clinical trial data with 6 months of follow-up showing an overall effectiveness of 91% against symptomatic infection and extensive real-world data from
millions of administered doses that clearly support the safety and efficacy of this vaccine. Clinical trial data did not include the time period after the Delta
variant emerged, so it does not reflect vaccine effectiveness against the variant causing the current wave of infections in the United States.
In addition to full FDA licensure for people age 16 years and older, the vaccine will continue to be administered under emergency use authorization (EUA)
for people age 12 through 15 years and for the administration of a third dose in certain immunocompromised individuals.
Comirnaty is in the identical formulation and presentation as the Pfizer-BioNTech COVID-19 Vaccine already authorized under the EUA. Therefore,
clinicians may use currently available inventory as licensed or authorized. The updated FDA Vaccine Information Fact Sheet for Recipients and
Caregivers should continue to be given to all approved age groups before vaccination. CDC is not releasing a Vaccine Information Statement
(VIS) for Comirnaty at this time.
CDC experts presented updated COVID-19 vaccine safety information obtained from reports to the Vaccine Adverse Events Reporting System (VAERS)
and the Vaccine Safety Datalink (VSD) system. Data confirm an estimated rate of severe allergic reaction (e.g., anaphylaxis) immediately following
vaccination with mRNA vaccines of about 5 per 1,000,000 doses administered. Additional data were presented on the epidemiology of rare instances of
myocarditis and myopericarditis following COVID-19 vaccination, consistent with earlier estimates showing the highest risk in males 12 through 49 years:
follow-up studies of longer-term outcomes are underway. Among 685 confirmed cases reported to VAERS with known outcome, 75% had already
recovered at the time of the report. The projected benefits from vaccination in preventing hospitalization, ICU admission, and death greatly outweighed
any risk from vaccination in all age groups analyzed. Surveillance reports continue to strongly support the overall acceptable safety of
currently available COVID-19 vaccines.
During the meeting’s final session, ACIP reviewed its framework for determining if a booster dose of COVID-19 vaccine should be recommended
for immunocompetent people who have completed a primary series. Data presented at this meeting indicate COVID-19 vaccines continue to maintain a
high level of protection against severe disease, hospitalization, and death, while protection against infection appears lower in recent months. ACIP will
continue to evaluate the ability of booster doses to improve protection, the impact of variants on vaccine effectiveness, and available safety data. If or
when FDA authorizes an additional dose of a COVID-19 vaccine for use as a booster dose in immunocompetent people, ACIP will reconvene to consider
data for a recommendation, possibly limiting the recommendation initially to people at the highest risk of severe disease outcomes. ACIP anticipates
reconvening in mid-September to consider additional data on safety and effectiveness of a booster dose for immunocompetent people in preparation for a
future vote. In the interim, it was noted that CDC recommends against administering COVID-19 vaccine boosters to immunocompetent people in the
absence of FDA authorization and ACIP recommendation. A CDC speaker noted that off-label use ahead of an ACIP recommendation is not permitted
under the conditions of the COVID-19 Vaccine Provider Agreement and potentially could affect provider liability
coverage under the Public Readiness and Emergency Preparedness (PREP) Act and patient protections under the Countermeasures Injury
Compensation Program.
Future ACIP Meetings
The next announced ACIP meetings are scheduled for September 29–30 (non-COVID-19 vaccine catch-up), and the regularly scheduled meeting
on October 20–21. An additional meeting in September may be announced; information about past and future ACIP
meetings may be found on the ACIP website.
Related Links
Back to top
Register now for IAC’s September 9 webinar! Our expert panel answers your questions
on preventing influenza during the COVID-19 pandemic.
As COVID-19 vaccination efforts continue, seasonal influenza vaccination remains essential to protect health and ease the burden on
healthcare systems. IAC will host a webinar titled The Continued Threat of Influenza and How to Sustain Influenza Vaccination
Efforts on September 9 at 1:00 p.m. (ET). Topics will include:
- Influenza surveillance in the United States and worldwide
- Changes in circulation of other common respiratory pathogens, e.g., RSV
- Changes in influenza vaccine strains and changes in influenza ACIP recommendations
- Communication issues providers may face regarding perceptions of the need for influenza vaccination
- A public perspective on the importance of influenza vaccination and advocacy for vulnerable populations
These topics will be addressed by speakers:
- Alicia Budd, MPH, Influenza Division of CDC’s National Center for Immunization and Respiratory Diseases (NCIRD)
- Robert H. Hopkins Jr., MD, University of Arkansas for Medical Sciences
- Gary Stein, MBA, Families Fighting Flu
Register now to be sure you don’t miss this informative session.
Back to top
"Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the
Advisory Committee on Immunization Practices, United States, 2021–22 Influenza Season" published in MMWR
Recommendations and Reports
CDC published Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization
Practices, United States, 2021–22 Influenza Season in the August 27 issue of MMWR Recommendations and Reports. A portion
of the summary showing the six updates appears below.
First, all seasonal influenza vaccines available in the United States for the 2021–22 season are expected to be quadrivalent.
Second, the composition of 2021–22 U.S. influenza vaccines includes updates to the influenza A(H1N1)pdm09 and influenza A(H3N2)
components.…
Third, the approved age indication for the cell culture–based inactivated influenza vaccine, Flucelvax Quadrivalent (ccIIV4), has been expanded
from ages ≥4 years to ages ≥2 years.
Fourth, discussion of administration of influenza vaccines with other vaccines includes considerations for coadministration of influenza vaccines and
COVID-19 vaccines. Providers should also consult current ACIP COVID-19 vaccine recommendations and CDC guidance concerning coadministration of
these vaccines with influenza vaccines. Vaccines that are given at the same time should be administered in separate anatomic sites.
Fifth, guidance concerning timing of influenza vaccination now states that vaccination soon after vaccine becomes available can be considered for
pregnant women in the third trimester. As previously recommended, children who need 2 doses … should receive their first dose as soon as possible
after vaccine becomes available to allow the second dose (which must be administered ≥4 weeks later) to be received by the end of October. For
nonpregnant adults, vaccination in July and August should be avoided unless there is concern that later vaccination might not be possible.
Sixth, contraindications and precautions to the use of ccIIV4 and RIV4 have been modified, specifically with regard to persons with a history of severe
allergic reaction (e.g., anaphylaxis) to an influenza vaccine. A history of a severe allergic reaction to a previous dose of any egg-based IIV, LAIV, or RIV
of any valency is a precaution to use of ccIIV4. A history of a severe allergic reaction to a previous dose of any egg-based IIV, ccIIV, or LAIV of any
valency is a precaution to use of RIV4. Use of ccIIV4 and RIV4 in such instances should occur in an inpatient or outpatient medical setting under
supervision of a provider who can recognize and manage a severe allergic reaction; providers can also consider consulting with an allergist to help
identify the vaccine component responsible for the reaction. For ccIIV4, history of a severe allergic reaction (e.g., anaphylaxis) to any ccIIV of any
valency or any component of ccIIV4 is a contraindication to future use of ccIIV4. For RIV4, history of a severe allergic reaction (e.g., anaphylaxis) to any
RIV of any valency or any component of RIV4 is a contraindication to future use of RIV4.
Updates for IAC influenza materials to reflect these six changes are in progress.
Access the MMWR article in HTML format or in PDF format.
Related Links
Back to top
“COVID-19 Vaccination Coverage among Adolescents Aged 12–17
Years—United States, December 14, 2020–July 31, 2021” published in MMWR Early Release
CDC published
COVID-19 Vaccination Coverage among Adolescents Aged 12–17 Years—United States, December
14, 2020–July 31, 2021 in the August 27 MMWR Early Release. A portion of the summary appears below.
As of July 31, 2021, coverage with ≥1 dose of COVID-19 vaccine among adolescents aged 12–17 years was 42%, and 32% had
completed the series. Series completion rates varied widely by state, ranging from 11% to 60%, and was 25% for adolescents aged 12–13 years,
30% for those aged 14–15 years, and 40% for those aged 16–17 years….
Improving adolescent COVID-19 vaccination coverage is crucial to reduce COVID-19–associated morbidity and mortality among adolescents and
can help facilitate safer reopening of schools for in-person learning.
Access the MMWR article in HTML format or in PDF format.
Related Link
Back to top
IAC updates its “Ask the Experts: COVID-19” web page to answer
questions about FDA licensure, vaccination during pregnancy, additional doses of mRNA vaccines for immunocompromised people, Guillain-Barré
syndrome, and myocarditis
IAC has again updated its Ask the Experts: COVID-19 web page to reflect important Q&As about the latest updates to
CDC recommendations for the use of COVID-19 vaccines. At this web page, you will find updates on FDA licensure, vaccination during pregnancy,
additional doses of mRNA vaccines for immunocompromised people, Guillain-Barré syndrome, and myocarditis.
The Ask the Experts: COVID-19 web page is updated regularly as guidance and vaccine authorizations change.
IAC's Ask the Experts gateway page leads you to 29 distinct web pages on a variety of topics with more than 1,000 common or challenging
questions and answers (Q&As) about vaccines and their administration. IAC's team of experts includes Kelly L. Moore, MD, MPH (team lead)
and Carolyn B. Bridges, MD, FACP.
Related Links
Back to top
IAC Spotlight! IAC's “Clinic Tools: Administering Vaccines”
gateway page provides resources from authoritative sources
IAC's Clinic Tools: Administering Vaccines gateway page is a collection of resources from IAC, CDC, and other organizations
related to administering vaccinations. This gateway page can be found by selecting the "Clinic Tools" tab in the middle of the blue banner
across the top of every Immunize.org web page and then selecting "Administering Vaccines" in the drop-down menu.
In the left-hand column of the page, you will find IAC's educational materials such as Administering Vaccines: Dose, Route, Site, and Needle
Size; Don’t Be Guilty of These Preventable Errors in Vaccine Administration; Skills Checklist for Vaccine Administration; and related
resources.
 
The right-hand column of the page features resources from CDC, including links to vaccine administration guidelines, “General Best Practice
Guidelines for Immunization,” and The Epidemiology and Prevention of Vaccine-Preventable Diseases ("The
Pink Book").
Visit the Clinic Tools: Administering Vaccines gateway page on Immunize.org.
Related Links
Back to top
Journalists interview IAC experts
Journalists seek out IAC experts to help explain vaccines to the public and policy makers. We help the media understand and communicate the complex
work vaccinators do. Here is a selection of our recent citations.
Related Link
Back to top
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
Back to top
Immunize.org Pages and Handouts
IAC updates its popular temperature logs for refrigerators and
freezers; available in Celsius and Fahrenheit
IAC recently updated its four temperature logs to help with proper vaccine storage and handling. IAC’s logs now refer
users to the COVID-19 Vaccine Addendum of CDC’s Vaccine Storage and Handling Toolkit.
 
 
Related Links
Back to top
IAC updates its Vaccine Storage
Troubleshooting Record to document occurrence and resolution of questionable or unacceptable vaccine storage events
IAC recently revised its Vaccine Storage Troubleshooting Record to refer users to the COVID-19 Vaccine Addendum of
CDC’s Vaccine Storage and Handling Toolkit.
Related Links
Back to top
IAC updates its handout for healthcare professionals
titled “Checklist for Safe Vaccine Storage and Handling”
IAC recently posted its updated resource for healthcare professionals titled Checklist for Safe Vaccine Storage and Handling. A new box
refers readers to CDC's website for information on COVID-19 vaccine storage and handling. New checklist items were added for vaccine inventory
management and equipment storage.
Related Links
Back to top
IAC updates its handout for healthcare
professionals titled "Don't Be Guilty of These Preventable Errors in Vaccine Administration!"
IAC recently posted its updated resource for healthcare professionals titled Don't Be Guilty of These Preventable Errors in Vaccine Administration!
Changes include the addition of a box to refer those seeking information on COVID-19 vaccines to CDC's website, greater
detail on options for buffering a digital data logger temperature probe, and several updated links.
Related Links
Back to top
IAC updates its handout for healthcare
professionals titled “Supplies You May Need at an Immunization Clinic”
IAC updated its handout for immunization providers titled Supplies You May Need at an Immunization Clinic. The handout was reorganized and new
useful materials to have on hand were added.
This one-page checklist provides an easy-to-use way to prepare. Supply categories include vaccines, documents, emergency supplies, Vaccine
Information Statements, and office supplies.
Related Links
Back to top
Echo: These updated IAC patient and
staff educational materials were released during July and August
IAC Express regularly provides readers with information about IAC’s new and updated educational materials for healthcare
professionals and handouts for patients. All IAC materials are free to distribute.
In case you missed them during recent weeks, IAC has made updates to these helpful materials:
IAC’s Updated Materials for Clinicians
Updated Ask the Experts Web Page
Related Links
Back to top
Vaccine Information Statements
Be sure to update your VISs! CDC releases 14 updated Vaccine Information Statements; translations in progress.
On August 9, CDC posted 14 updated Vaccine Information Statements (VISs). Access these VISs on their respective IAC web pages by clicking on the
links below.
- DTaP
(Diphtheria, Tetanus, Pertussis)
- Haemophilus influenzae type b (Hib)
- HPV
(Human Papillomavirus)
- Influenza, inactivated or recombinant
- Influenza, live intranasal
-
Meningococcal ACWY
- Meningococcal B
- MMR
(Measles, Mumps, and Rubella)
- MMRV (Measles, Mumps, Rubella, and Varicella)
- Pneumococcal Conjugate (PCV13)
- Polio
- Td
(Tetanus, Diphtheria)
- Tdap
(Tetanus, Diphtheria, Pertussis)
- Varicella (Chickenpox)
CDC encourages providers to begin using these VISs immediately; however, existing supplies of the previous editions may be used until they are
depleted.
IAC will produce translations of these new VISs and post them on Immunize.org as they become available over the next several weeks. Translations of
previous VIS versions may be used until new translations become available. CDC states that the corresponding up-to-date English-language VIS must also
be supplied when providing an out-of-date translation.
Related Links
Back to top
Featured Resources
It’s time to kick off flu vaccine season.
Don’t delay; order IAC's flu vaccine buttons and stickers for staff and patients today!
After you order your vaccine, don’t forget to order your buttons and stickers. IAC “FLU VACCINE” buttons and
stickers are ready to ship! Their bright red color helps broadcast your important message about the need for influenza vaccination. And the
cost is reasonable.
“FLU VACCINE” BUTTONS
The button measures 1.25" across and carries a bold message! Pin on lab coats, uniforms, other clothing, tote bags, or backpacks to show support
for flu vaccine.
Buttons are delivered in bags of 10 buttons per bag.
Click here
for pricing and ordering information for "FLU VACCINE" buttons.
“FLU VACCINE” STICKERS
Measuring 1.5" across, these stickers adhere well to clothing and have an easy-peel-off backing.
Stickers are delivered to you cut individually (not on rolls)—available in bundles of 100.
Click here for pricing and ordering information for “FLU VACCINE” stickers.
Visit Shop IAC for additional
items, including "Vaccines Save Lives" enamel pins, patient record cards, and a vaccine administration training video.
Back to top
Teens are back in school, but
many are still missing vaccinations! Check out updated www.Give2MenACWY.org website to increase coverage for the MenACWY booster and other
adolescent vaccinations.
IAC’s www.Give2MenACWY.org website promotes the importance of adolescent vaccination, including administering the recommended
booster dose of MenACWY vaccine at age 16. Many teens are behind on vaccines because of the pandemic, so adolescent vaccination is more
important than ever.
Original materials on this colorful website for healthcare professionals have been updated to incorporate the 2020 ACIP meningococcal vaccine recommendations and the most recent vaccine coverage statistics from CDC’s National
Immunization Survey–Teen (NIS–Teen). One particularly popular resource on the site is the updated Algorithm for MenACWY Immunization in Adolescents 11–18 Years of Age.
The website’s navigation structure makes locating information a breeze; it is divided into five easy-to-access sections:
The site
also categorizes materials according to whether they are primarily of interest to providers, to adolescents, or to parents.
Visit
Give2MenACWY.org and enjoy browsing (and deploying) its bountiful resources.
Related Links
Back to top
American Hospital Association launches new PSA campaign to encourage hesitant hospital
workers to get vaccinated
The American Hospital Association (AHA) has released three public service announcements (PSAs) featuring clinicians sharing their reasons for getting
vaccinated against COVID-19 vaccine and encouraging their colleagues and communities to overcome concerns by seeking guidance from the trusted
healthcare professionals in their lives. Each of the PSAs, which also are available with Spanish subtitles, can be accessed on AHA's vaccine confidence
web page.
Access the direct links to each PSA below.
Related Links
Back to top
Notable Publications
"Safety of the BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Setting" published in New England Journal of
Medicine
In the August 25 issue, New England Journal of Medicine published Safety of the BNT162b2 mRNA COVID-19 Vaccine in a Nationwide
Setting. A portion of the Conclusions section appears below.
In this study in a nationwide mass vaccination setting, the BNT162b2 vaccine was not associated with an elevated risk of most of the adverse events
examined. The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse
event and of many other serious adverse events was substantially increased after SARS-CoV-2 infection....
"Vaccinations against COVID-19 May Have
Averted up to 140,000 Deaths in the United States" published in Health Affairs
In the August 18 issue, Health Affairs published Vaccinations against COVID-19 May Have Averted up to 140,000 Deaths in the United
States. The abstract appears below.
COVID-19 vaccination campaigns continue in the United States, with the expectation that vaccines will slow transmission of the virus, save lives, and
enable a return to normal life in due course. However, the extent to which faster vaccine administration has affected COVID-19-related deaths is unknown.
We assessed the association between US state-level vaccination rates and COVID-19 deaths during the first five months of vaccine availability. We
estimated that by May 9, 2021, the US vaccination campaign was associated with a reduction of 139,393 COVID-19 deaths. The association varied in
different states. In New York, for example, vaccinations led to an estimated 11.7 fewer COVID-19 deaths per 10,000, whereas Hawaii observed the
smallest reduction, with an estimated 1.1 fewer deaths per 10,000. Overall, our analysis suggests that the early COVID-19 vaccination campaign was
associated with reductions in COVID-19 deaths. As of May 9, 2021, reductions in COVID-19 deaths associated with vaccines had translated to value of
statistical life benefit ranging between $625 billion and $1.4 trillion.
Back to top
“A Megastudy of Text-Based Nudges
Encouraging Patients to Get Vaccinated at an Upcoming Doctor’s Appointment” published in Proceedings of the National Academy of
Sciences
In the May 18 issue, Proceedings of the National Academy of Sciences published A Megastudy of Text-Based Nudges Encouraging Patients to Get
Vaccinated at an Upcoming Doctor’s Appointment. The abstract appears below.
Many Americans fail to get life-saving vaccines each year, and the availability of a vaccine for COVID-19 makes the challenge of encouraging
vaccination more urgent than ever. We present a large field experiment (N = 47,306) testing 19 nudges delivered to patients via text message and
designed to boost adoption of the influenza vaccine. Our findings suggest that text messages sent prior to a primary care visit can boost vaccination rates
by an average of 5%. Overall, interventions performed better when they were 1) framed as reminders to get flu shots that were already reserved for the
patient and 2) congruent with the sort of communications patients expected to receive from their healthcare provider (i.e., not surprising, casual, or
interactive). The best-performing intervention in our study reminded patients twice to get their flu shot at their upcoming doctor's appointment and
indicated it was reserved for them. This successful script could be used as a template for campaigns to encourage the adoption of life-saving vaccines,
including against COVID-19.
Back to top
MMWR Recap: COVID-
19 cases and hospitalizations by vaccination status and vaccine effectiveness estimates
CDC recently published several articles first distributed as MMWR Early Releases:
- New COVID-19 Cases and Hospitalizations among Adults, by Vaccination Status—New York, May 3–July 25, 2021
(MMWR, August 27, HTML format or PDF format)
- Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines against COVID-19 Associated Hospitalizations among
Adults—United States, March–July 2021 (MMWR, August 27,
HTML format or PDF format)
- Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection among Nursing Home Residents before and
during Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant—National Healthcare Safety Network, March 1–August 1, 2021
(MMWR, August 27, HTML format or PDF format)
- Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection among Frontline Workers before and during B.1.617.2 (Delta)
Variant Predominance—Eight U.S. Locations, December 2020–August 2021 (MMWR, August 27,
HTML format or PDF format)
- SARS-CoV-2 Infections and Hospitalizations among Persons Aged ≥16 Years, by Vaccination Status—Los Angeles County,
California, May 1–July 25, 2021 (MMWR, August 27,
HTML format or PDF format)
Related Link
- MMWR gateway page provides access to MMWR Weekly and its companion publications
Back to top
Global News
CDC and WHO report on progress toward polio eradication, worldwide, in this week's MMWR and Weekly
Epidemiological Record, respectively
CDC published Progress toward Polio Eradication—Worldwide, January 2019–June 2021 in the August 27 issue of MMWR. On the same day, WHO's Weekly Epidemiological Record published a similar
article titled Progress towards Polio Eradication—Worldwide, January 2019–June 2021. A media summary of the
MMWR article appears below.
In 2020, wild polio cases increased in Afghanistan and decreased in Pakistan compared with 2019, and rising rates of under-immunized children,
as well as COVID-19 disruptions, led to increases in outbreaks of circulating vaccine-derived polio in 13 additional countries. Wild poliovirus
continues to circulate in two countries: Afghanistan and Pakistan. In 2020, polio cases increased in Afghanistan and decreased in Pakistan compared
with 2019. However, circulating vaccine-derived poliovirus cases continue to spread globally, with outbreaks reported in 32 countries, including 13 new
countries in 2020. As the COVID-19 pandemic disrupts polio eradication efforts, the Global Polio Eradication Initiative and partners launched an updated
five-year eradication strategy in June 2021. The strategy focuses on stopping wild polio circulation and vaccine-derived polio outbreaks by responding
quickly to outbreaks, widening use of a new oral polio vaccine, integrating polio eradication efforts with other country-level outbreak responses and health
efforts, and ensuring accountability at all levels to create a polio-free world.
Related Links
Back to top
Upcoming Events
Watch today (September 1 at 5 p.m. ET): National Academy of Medicine’s webinar “COVID-19 Conversations #21 the Fourth
Wave: Vaccines, Variants, and the Future”; CME available
On September 1 at 5:00 p.m. (ET), the National Academy of Medicine (NAM) will offer a webinar titled COVID-19 Conversations #21 the Fourth Wave: Vaccines, Variants, and the Future.
This webinar will provide an update on the current state of COVID-19, focusing specifically on the Delta variant, implications for children under the age of
12, what the rise of this highly infectious variant means for vaccinated and unvaccinated adults and adolescents, and what it will take to move past this
surge and end the pandemic.
Live webinar participants can earn 1.5 CPH, CME, CNE, or CHES continuing education credits. Participants must watch the entire webinar, including the
Q&A, to be eligible for CE credits.
Back to top
Also today (September 1 at 3 p.m.
ET): Nevada Immunization Learning Exchange’s webinar "The State of the Pandemic: Where Do We Stand and Where Do We Go from
Here?"; CEU available
On September 1 at 12:00 p.m. (PT), Nevada Immunization Learning Exchange (NILE) will offer a webinar titled The State of the Pandemic: Where Do We Stand and Where Do We Go from Here?
During this presentation, the co-hosts of Unbiased Science (public health scientist Dr. Jessica Steier and immunologist/microbiologist Dr. Andrea
Love) will discuss new and emerging data regarding the Delta variant, as well as risks for future mutations. They will also discuss common vaccine myths
and the evidence to debunk those myths, as well as ways to have conversations with vaccine-hesitant people in healthcare settings.
This program offers one free CEU for nurses, Nevada pharmacists, and CHWs, upon completion of the post-webinar survey.
Archived NILE
webinars are available to watch.
Back to top
IAC's Calendar of Events
provides information about federal, state, and national partners' vaccination conferences, as well as professional societies' annual
meetings
IAC maintains a Calendar of Events on its website for healthcare professionals at www.immunize.org/calendar. This is an easy way to find out about upcoming
regional, state, and national conferences, workshops, and electronic continuing educational opportunities. The calendar also includes special weeks of
observances.
If you have a vaccination-related event that you would like your colleagues to know about via this Calendar of Events, email IAC.
You can locate IAC's "Calendar of Events" web page in the “Guide to Immunize.org” index at the bottom of every
Immunize.org web page.
Back to top
Immunization PSAs from the Archive
In this compelling PSA from Pennsylvania Department of Health, we hear Tim Baker, an infant diagnosed with pertussis,
struggle to breathe during coughing fits
In this compelling public service announcement (PSA) from the Pennsylvania Department of Health, an unvaccinated infant struggles
to breathe during coughing fits caused by pertussis. This PSA is part of a collection curated by vaccine expert William L. Atkinson, MD, MPH, that spans
a period of more than 50 years.
Previous PSAs featured in "Immunization PSAs from the Archive” are available when viewing this Vimeo
video.
Back to top
|
|
